首页 | 本学科首页   官方微博 | 高级检索  
     


Combined glycoprotein IIb/IIIa receptor inhibition and low-dose fibrinolysis for peripheral arterial thrombosis.
Authors:Krishna J Rocha-Singh  Janiece Trokey
Affiliation:Prairie Heart Institute, St. John's Hospital and Prairie Education and Research Cooperative, Department of Cardiology, Southern Illinois University School of Medicine, Springfield, Illinois 62794, USA. ksingh@prairieheart.com
Abstract:This feasibility study evaluated the therapeutic potential of combined GP IIb/IIIa receptor inhibition with abciximab and low-dose fibrinolysis with reteplase for treatment of acute femoropopliteal thrombosis. The simultaneous intra-arterial administration of abciximab in conjunction with low-dose reteplase (< or = 0.5 U/hr) was safe in 13 patients; 2 patients experienced major hemorrhagic complication at a reteplase dose of 1 U/hr. The primary success rate was 100%; all patients experienced an excellent clinical response with no clinical evidence of distal embolization. No patient required repeat endovascular or surgical revascularization during mean follow-up of 9.3 months. This promising new thrombolytic strategy for the treatment of peripheral arterial occlusive disease requires further study.
Keywords:GP IIb/IIIa receptor inhibition  fibrinolysis
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号